Cell Press and the ISSCR enter an exciting new publishing partnership
Cambridge, MA, October 24, 2012 -- Cell Press is delighted to announce that it has been chosen by the International Society for Stem Cell Research, ISSCR, to publish its new Open Access journal Stem Cell Reports.
As the most prominent scientific society in the stem cell field, the ISSCR provides a unique platform for the stem cell community to promote the exchange and dissemination of information and ideas, with a focus on quality and outreach. In line with the ISSCR’s mission to facilitate progress in all areas of stem cell science, Stem Cell Reports will provide a new open access venue for important developments ranging from basic advances to clinical translation.
Having recognized the growth and importance of the stem cell field at an early stage, Cell Press is now excited to expand its contribution to the community even further through this new partnership with the ISSCR. With Stem Cell Reports, Cell Press continues todevelop the publishing options available to stem cell researchers for communication of their work.
"We are thrilled to work with the ISSCR to launch and publish Stem Cell Reports. At Cell Press we welcome the opportunity to partner with societies who are looking to launch new Open Access journals to extend the ways in which they serve their members and the scientific community,” said Dr. Emilie Marcus, CEO of Cell Press.
Shinya Yamanaka, Nobel Laureate and President of the ISSCR, said, "We are delighted by this new partnership with Cell Press and believe the new journal will provide a much-needed forum to highlight new developments and ideas in this rapidly-evolving field."
Professor Christine Mummery will be the Editor of Stem Cell Reports. Christine is Professor of Developmental Biology and Chair of the Department of Anatomy and Embryology at Leiden University Medical Center. Her primary research focus is currently the development and use of stem cells in cardiovascular development and disease. She will be joined by four Associate Editors and a distinguished Editorial Board.
Stem Cell Reports will begin accepting submissions in December 2012 for publication in the inaugural issue, due to be published in June 2013. There will be a number of article types, including full-length papers and shorter formats. Stem Cell Reports authors will retain full copyright over their articles, which will be published using Creative Commons licenses.
This exciting new launch builds upon the already successful affiliation between the ISSCR and Cell Stem Cell (a Cell Press journal), which launched in 2007 and already has an impact factor of 25.421.
Cell Press has always placed a high priority on enabling authors to disseminate published research widely and easily, and offers a variety of options to make content widely accessible, both for Cell Press owned titles and for journals published on behalf of learned societies. These options include free featured articles, sponsored-access opportunities, free access to all content after 12 months, and publication in the Cell Press Open Access journal Cell Reports.
About Cell Press
Cell Press is committed to improving scientific communication through the publication of world-renowned, highly cited, exciting research and reviews. Cell Press journals remain synonymous with excellence and innovation in scientific publishing. Cell Press is also committed to providing value to authors and readers through innovation in online content, mobile access, and article formats and is introducing new experiences, such as webinars and the Cell Symposia conference series, that complement our journals. Cell Press strives to ensure that our high-impact journals are widely accessible through public access, funding-body agreements, and open-access initiatives.
Find out more at www.cell.com
About the ISSCR
The International Society for Stem Cell Research is an independent, nonprofit membership organization established to promote and foster the exchange and dissemination of information and ideas relating to stem cells, to encourage the general field of research involving stem cells and to promote professional and public education in all areas of stem cell research and application.
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier’s online solutions include ScienceDirect, Scopus, Reaxys, ClinicalKey and Mosby’s Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai’s Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group plc, a world leading provider of professional information solutions. The group employs more than 30,000 people, including more than 15,000 in North America. Reed Elsevier Group plc is owned equally by two parent companies, Reed Elsevier PLC and Reed Elsevier NV. Their shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RUK and ENL.
Elisabeth (Lisa) Lyons